DNJ-20 - CAS 3081926-49-7

DNJ-20 is an α-glucosidase inhibitor with an IC50 of 55.3 μg/mL. It exhibits broad-spectrum activity against SARS-CoV-2. By interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), DNJ-20 hinders the proper processing of viral glycoproteins, thus blocking the formation and infection of viral particles. It is effective against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43, with IC50 values reaching up to 1.49 μM. DNJ-20 can be utilized for pan-coronavirus research.

SARS-CoV, glycosidase

Microbiology/Virology, Metabolism

3081870

C31H41NO10

587.658

O(CCCCCCCCCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1)C2=C3C(OC(=CC3=O)C4=CC(O)=C(O)C=C4)=CC(O)=C2

-20°C

Ice Packs

Small Compound